Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters

9Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Tumor heterogeneity is an important concept when assessing intratumoral variety in vascular phenotypes and responses to antiangiogenic treatment. This study explored spatiotemporal heterogeneity of vascular alterations in C6 glioma mice during tumor growth and antiangiogenic treatment on serial MR examinations (days 0, 4, and 7 from initiation of vehicle or multireceptor tyrosine kinase inhibitor administration). Transvascular permeability (TP) was quantified on dynamic-contrast-enhanced MRI (DCE-MRI) using extravascular extracellular agent (Gd-DOTA); blood volume (BV) was estimated using intravascular T2 agent (SPION). With regard to region-dependent variability in vascular phenotypes, the control group demonstrated higher TP in the tumor center than in the periphery, and greater BV in the tumor periphery than in the center. This distribution pattern became more apparent with tumor growth. Antiangiogenic treatment effect was regionally heterogeneous: in the tumor center, treatment significantly suppressed the increase in TP and decrease in BV (ie, typical temporal change in the control group); in the tumor periphery, treatment-induced vascular alterations were insignificant and BV remained high. On histopathological examination, the control group showed greater CD31, VEGFR2, Ki67, and NG2 expression in the tumor periphery than in the center. After treatment, CD31 and Ki67 expression was significantly suppressed only in the tumor center, whereas VEGFR2 and α-caspase 3 expression was decreased and NG2 expression was increased in the entire tumor. These results demonstrate that MRI can reliably depict spatial heterogeneity in tumor vascular phenotypes and antiangiogenic treatment effects. Preserved angiogenic activity (high BV on MRI and high CD31) and proliferation (high Ki67) in the tumor periphery after treatment may provide insights into the mechanism of tumor resistance to antiangiogenic treatment.

References Powered by Scopus

Angiogenesis in cancer and other diseases

8021Citations
N/AReaders
Get full text

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing

6412Citations
N/AReaders
Get full text

Molecular mechanisms and clinical applications of angiogenesis

4400Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Nanomedicine for brain cancer

93Citations
N/AReaders
Get full text

Photodynamic creation of artificial tumor microenvironments to collectively facilitate hypoxia-activated chemotherapy delivered by coagulation-targeting liposomes

18Citations
N/AReaders
Get full text

Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kim, C., Suh, J. Y., Heo, C., Lee, C. K., Shim, W. H., Park, B. W., … Kim, J. K. (2018). Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters. Cancer Medicine, 7(8), 3921–3934. https://doi.org/10.1002/cam4.1624

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

73%

Professor / Associate Prof. 1

9%

Lecturer / Post doc 1

9%

Researcher 1

9%

Readers' Discipline

Tooltip

Engineering 5

45%

Biochemistry, Genetics and Molecular Bi... 4

36%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Chemistry 1

9%

Save time finding and organizing research with Mendeley

Sign up for free
0